How to track treatment of equity awards for Business Merger Transactions

Track equity award treatment by reconciling grant-level records to the governing plans, individual instruments, and merger agreement, then documenting the disposition and calculation for each grant or genuinely identical cohort. For the acquirer, the deliverable is an evidence-backed tracker separating cancellation, cash payment, replacement, and unresolved exceptions. It should connect each conclusion to source language, test the applicable formula, and assign funding and implementation questions. Keep contractual entitlement, calculation assumptions, and payment readiness separate so a balanced capitalization schedule does not conceal unsupported treatment decisions.

When to use this workflow

Use this workflow when acquirer counsel receives an award schedule, negotiates merger award provisions, or reviews capitalization updates before closing. It is especially useful where options, restricted stock units (RSUs), and performance awards receive different treatment or individual agreements introduce acceleration exceptions.

This is a general review workflow, not a complete compensation, tax, securities, or closing workstream. It uses a US baseline focused on Delaware corporate mergers. Other formation jurisdictions, entity types, and cross-border awards require separate analysis. Award rights depend on the instruments, governing law, facts, and negotiated terms.

Do not infer a cash-out formula from statutory succession. Delaware Code §259(a) addresses the survivor’s succession to property, rights, liabilities, and duties; it does not prescribe award-specific cash or replacement calculations. Read the operative documents for those answers. (delcode.delaware.gov)

What you need

Collect a dated capitalization snapshot and grant-level export identifying holders, grant IDs, award types, quantities, exercise prices, vesting schedules, performance periods, and prior exercises, cancellations, and settlements. Request a movement bridge through the contractual measurement time.

The supporting source set should include:

• Equity plans, amendments, individual grants, acceptance evidence, and relevant approval records.
• Employment, severance, change-in-control, and retention agreements affecting acceleration or settlement.
• The operative merger agreement, definitions, award provisions, disclosure schedules, and amendments.
• Equity-administration and relevant payroll records supporting service status and prior payments.
• Proposed replacement instruments, calculation workpapers, funding assumptions, and specialist questions.

Assign stable document IDs and preserve version and execution status. A form grant does not establish which terms apply to every holder. Mark missing instruments as evidence gaps rather than assuming no exception exists. Restrict access to holder-level personal and payroll information to the review team that needs it.

Use the template

The Business Merger Transactions — Equity award treatment tracker connects treatment conclusions to evidence and implementation dependencies. Copy this table into your working document or spreadsheet. Use one row per grant unless all treatment-relevant attributes support grouping; preserve a linked grant list for every cohort.

In Evidence, enter document IDs and section or page citations, including schedule exceptions. Vesting / triggers should distinguish snapshot status from status at the contractual measurement time.

In Treatment / formula, state the disposition and calculation rule, not merely “per agreement.” Test / uncertainty should link workpaper cells and distinguish verified inputs from assumptions. Funding / timing separates immediate cash from deferred obligations and identifies the timing source. Owner / action records responsibility, status, next decision date, and resolution evidence. Keep detailed calculations in linked workpapers rather than overcrowding the tracker.

Step by step

1. Fix the document baseline and measurement event

Identify the agreement version and event governing each treatment rule. Signing, closing, the effective time, and payment are distinct events. Extract the relevant definitions rather than assuming the capitalization export uses identical terminology.

Preserve the original snapshot. Ask the target to identify intervening grants, exercises, forfeitures, settlements, and service-status changes, then reconcile them through a dated movement bridge.

Record: baseline document IDs, snapshot date, contractual measurement event, and bridge owner. Mark affected rows provisional until the required refresh is reviewed.

2. Reconcile the award population

Match grant IDs across capitalization records, the administration export, individual instruments, and relevant payroll records. Investigate duplicate IDs, quantity differences, missing amendments, and awards held by former employees or nonemployee service providers.

Separate outstanding awards from shares already issued through exercise or settlement. Check the shareholder consideration schedule to avoid counting the same interest twice. Reconcile by award category and holder, not just aggregate units or value.

Record: reconciled quantities, supporting references, and unexplained differences. Assign missing evidence to a named owner; an apparently reasonable total is not a substitute for reconciliation.

3. Map each grant to the merger provision

Read the award section with its definitions, disclosure exceptions, plans, and individual instruments. Determine whether each category is cancelled without payment, cashed out, replaced, assumed, or continued. Do not collapse cancellation of an original award and creation of a replacement right into a single unexplained status.

The Dayforce/Dawn agreement, §2.03, illustrates meaningful distinctions: vested options receive a positive-spread cash calculation, unvested options receive no consideration, vested RSUs receive cash, and unvested RSUs and performance awards generally receive replacement cash rights subject to specified terms and exceptions. This is negotiated wording, not a market standard. (sec.gov)

Record: the applicable provision, disposition, exceptions, and any conflict or authority question. Refer inconsistent instruments to counsel rather than assuming the merger agreement overrides them.

4. Resolve vesting, performance, and acceleration dependencies

Separate time vesting from performance determinations. For performance awards, identify the measurement period, contractual achievement assumption, service condition, and any required certification. Do not replace missing evidence with an estimated achievement percentage.

For acceleration, identify every required event. Determine whether the transaction alone suffices or whether a specified termination or another event is also necessary. Examine service status and replacement terms against the actual trigger language.

Use separate rows where grants have different triggers or unresolved facts. Route tax-sensitive settlement timing and cross-border questions to the appropriate specialists before treating a payment date as approved.

Record: supported vesting status, performance assumption, trigger evidence, and assigned specialist questions.

5. Test the treatment calculations independently

Expose each input in a workpaper: eligible units, exercise price, contractual consideration, conversion factor, performance multiplier, and rounding rule. State the formula in words alongside its spreadsheet implementation.

Test partial vesting, fractional results, and options with exercise prices equal to or above consideration. Use zero-payment cancellation only where supported by the documents. For replacements, check both the replacement quantity or value and retained vesting terms.

Separate gross entitlement from withholding and net payment. Do not insert an assumed tax rate to make the schedule appear complete. Have a second reviewer check source inputs and formulas, not only arithmetic.

Record: workpaper cells, results, rounding treatment, reviewer disposition, and unresolved assumptions.

6. Verify funding, timing, and implementation authority

Identify the obligor, funding source, administrator, payment trigger, and replacement documentation for each category. Distinguish the party legally responsible for payment from the team operationally processing it.

Keep merger approval separate from award implementation. Delaware Code §251(b)–(c) addresses board approval and generally stockholder adoption of the merger agreement, subject to statutory exceptions. It does not alone establish every award-related approval or consent requirement. Check the plans, instruments, applicable authority, and proposed actions. (delcode.delaware.gov)

Ask finance and payroll to confirm implementation against the reviewed terms, including any deferred payment dependencies.

Record: obligor, funding and administration owners, timing citation, approval questions, replacement-document status, and evidence still needed.

7. Review exceptions and release a controlled tracker

Reconcile reviewed totals to consideration and funding workpapers, keeping deferred replacement obligations separate from immediate cash. Recheck agreement amendments that change definitions, treatment, or timing.

Distinguish evidence pending, legal interpretation pending, calculation verified, and implementation ready. A verified calculation does not establish that its underlying entitlement is approved. Record who accepts a commercial risk without marking an unresolved legal or evidence issue as resolved.

Record: reviewer disposition, source version, remaining owner and decision date, and exception rationale. Release the tracker with its workpapers and an explicit open-issue list appropriate to the handoff’s purpose.

Worked example

Fictional scenario: Alder Harbor Acquisition Corp. is acquiring Meridian Circuit Inc. All parties, records, amounts, and provisions below are fictional.

Merger agreement MA-01 §2.4 uses $24 per share. Section 2.4(a) cancels vested options for units multiplied by the positive difference between $24 and exercise price; options without a positive spread receive nothing. It requires buyer-funded payment through the survivor’s first regular payroll after the effective time. Section 2.4(b) replaces unvested RSUs with cash rights at $24 per unit, preserving existing service vesting and applicable acceleration terms. Section 2.4(c) uses target performance units except as specified on Schedule E.

CAP-01 lists 1,000 vested options at an $8 exercise price, 600 unvested RSUs, and 400 target performance units. EMP-22 §5 contains an additional termination trigger potentially affecting the RSUs. Schedule E identifies the performance grant as an exception, but its operative attachment is missing. The movement bridge remains outstanding.

The review prevents three different errors. The $16,000 option result is supported but remains subject to population changes. The $14,400 RSU right is not automatically closing cash; acceleration facts could change its treatment or timing. The $9,600 performance sensitivity belongs outside approved entitlement totals because the identified exception is unavailable. Finance receives supported amounts and separately identified uncertainties, not a misleading combined payment figure.

Common mistakes

• Grouping by label alone. Separate grants with different prices, vesting, acceleration, or exceptions, even if all are called RSUs.
• Freezing signing-date vesting. Preserve the snapshot but reconcile movements through the contractual measurement event.
• Treating a form as holder-specific evidence. Obtain the applicable instrument or retain an assigned evidence gap.
• Equating gross value with cash to release. Separate withholding review, deferred rights, obligor, and payment timing.
• Closing an issue through commercial acceptance alone. Preserve the acceptance while separately assigning unresolved entitlement, documentation, or authority questions.

Final quality check

• Every outstanding grant appears once; issued shares remain distinct.
• Quantities reconcile to the dated population and movement bridge.
• Treatment citations identify operative versions and applicable exceptions.
• Vesting, performance, and acceleration have evidence or assigned questions.
• Inputs, formulas, rounding, and exception cases received independent verification.
• Funding distinguishes immediate payments from deferred or replacement obligations.
• Open issues have owners and decision dates; resolved items retain evidence and reviewer approval.

Complete the workflow with DecoverAI

DecoverAI is the Legal Intelligence Platform for litigation and transactions. Its due diligence capabilities support bulk document classification and tabular review across documents, helping counsel organize award materials for review. (decover.ai) In contract review, lawyers can specify the represented party and deal instructions; findings quote and locate clauses, rank severity, and identify missing language as not present. Lawyers retain judgment over entitlement, calculations, and implementation. Book a demo to discuss this review workflow. (decover.ai)

Frequently asked questions

Can one row cover all grants under a plan?

Only after checking treatment-relevant terms and facts. Different exercise prices, vesting dates, performance assumptions, or individual exceptions call for separate rows or a linked grant-level schedule.

What if an award instrument conflicts with the merger agreement?

Record both provisions and affected grants. Assign counsel to determine the contractual and legal path, including amendment, approval, or consent questions. Do not silently select the easier formula.

How should missing performance evidence affect calculations?

Separate the contractual rule from unsupported inputs. Label sensitivity calculations unapproved and exclude them from confirmed entitlement totals until the missing evidence or authorized determination is obtained.

When is the tracker ready for handoff?

Identify whether the handoff supports negotiation, funding preparation, or implementation. Verify the sources and calculations needed for that purpose, confirm receiving owners, and explicitly assign remaining questions rather than giving a blanket completion label.

Sources

• Delaware Code, Title 8, §§251 and 259: merger authorization and statutory succession within Delaware corporate-law scope.
• Dayforce/Dawn merger agreement, SEC-filed Exhibit 2.1, §2.03: negotiated award-treatment provisions illustrating category-specific treatment, not market standards.

This guide is general information about legal workflows, not legal advice for any matter. It was drafted and reviewed with AI assistance. The worked example is fictional. Contract rights and procedure depend on the governing law, the actual wording, and the facts, so check the cited sources and the rules that apply in your jurisdiction before relying on it.